• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Hydroxychloroquine Use May Protect Against the Development of Diabetes in RA Patient

Hydroxychloroquine Use May Protect Against the Development of Diabetes in RA Patient

August 28, 2007 By Arthritis Center

Hydroxychloroquine (Plaquenil) is a commonly used disease modifying anti-rheumatic drug (DMARD) for RA that has known beneficial effects on blood glucose and lipids.  However, whether its use can prevent the onset of diabetes in RA patients prescribed it to reduce articular signs and symptoms has not been evaluated.  Here, Wasko et al (JAMA 2007; 298: 187) explore this issue using prospective data from the Arthritis, Rheumatism, and Aging Medical Information System (ARAMIS) database.

Methods and Results:

Results as published from his study were summarized as presented at the 2006 American College of Rheumatology Meeting.

Conclusions:

In a large cohort of RA subjects, any exposure to HCQ was protective against incident self-reported diabetes, independent of confounding factors.

Editorial Comment:

These are interesting results that suggest an added benefit of HCQ use in RA and suggest a link between the immune system and the pathogenesis of Type II diabetes.  The exact mechanisms of HCQ efficacy in RA is unknown, but recent data suggests that inhibition of signaling through Toll-like receptors, a participant in innate immune responses, may be a possible mechanism.  Whether inhibition of Toll-like receptors by HCQ is also the mechanism of prevention of incident diabetes has not been established.

It should be pointed out that the incidence of diabetes was not especially high in the cohort enrolled in this study, and the prevalence of diabetes has not been found to be increased in RA patients.  Thus, HCQ would not be used solely for the prevention of incident diabetes in RA, but should have some basis in controlling articular signs and symptoms.  However, combination therapies with HCQ in RA have been shown to be more efficacious than monotherapies.  This, coupled with the low toxicity of HCQ in general, is additional reasons not to discourage the liberal use of HCQ in RA patients.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy